Pharmaceutical Executive-06-01-2021

Pandemic-reinforced principles of successful drug launch.

In today’s fragmented commercial environment, navigating a more complex set of challenges while adapting new approaches to product launch is critical for biopharma brand teams.

How Gilead readied remdesivir for the COVID challenge.

Inside Regeneron’s monoclonal antibody development to treat COVID.

Past lessons, strong resolve, and complex coordination propel J&J’s vaccine efforts.

Thrust into a commercial-stage company in just months, Moderna moves full steam ahead.

College roommates, industry partnerships help bring Pfizer vaccine to fruition.

Pharm Exec’s latest listing of the top global biopharma sales producers captures the critical business and public health balancing act that was required in the Year of COVID—reinforcing the staying power of building brand value while championing medical innovation.

What are the reasons behind the slump and what does the future hold?

Building on a lifelong passion for biomedical research, and then its application in policy and health equity as a leader in various interconnected settings, Michelle McMurry-Heath, president and CEO of BIO, is uniquely positioned as a “translator” for science and social advocacy—and speaking stakeholders to action.

A business framework for pricing and broader brand strategy.

How the UK is making progress in this hi-tech field.

Pandemic triggers urgency around supply chain initiatives.

Separate pushes for vaccine equity, legislation to lower drug costs.

Looking Back at 1997–1999.

Combined powers of synbio and biopharma point to bright future for industry.

A letter on the June 2021 issue of Pharm Exec from Chairman and Founder of MJH Life Sciences, Mike Hennessy Sr.

Click the title above for a link to open the Pharmaceutical Executive June 2021 issue in an interactive PDF format.